Fig. 2
From: Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor
50% responder rates for the prevention of chronic migraine. The numbers on top of the columns reflect therapeutic gain (verum minis placebo)
Fig. 2 | Neurological Research and Practice